Oral 1.alpha.-hydroxyprevitamin D in composition and method for treating psoriasis
AssigneeBone Care International, Inc.
InventorsJoyce C. Knutson, Charles R. Valliere, Charles W. Bishop
Life of this patent
Estimating the term…
Abstract
Method of treating psoriasis by administering orally a 1.alpha.-hydroxyprevitamin D. This previtamin D form treats psoriasis without significant risk of hypercalcemia associated with other oral dosing of vitamin D forms. The 1.alpha.-hydroxyprevitamin is compounded into a pharmaceutical composition in combination with a pharmaceutically acceptable excipient.
Claims30
A composition in unit dosage form comprising an oral 1.alpha.-hydroxyprevitamin D formulation, said formulation comprising:
- an amount of 1.alpha.-hydroxyprevitamin D which is 1.alpha.-hydroxyprevitamin D.sub.2 or 1.alpha.-hydroxyprevitamin D.sub.4 in a form which is substantially pure, crystalline and solvent-free, stable at room temperature and substantially free of its thermal isomer, and
- a pharmaceutically acceptable carrier.
A method for treating psoriasis in a human being suffering therefrom, comprising administering orally to the human being a therapeutically effective amount of a solvent-free 1.alpha.-hydroxyprevitamin D which is 1.alpha.-hydroxyprevitamin D.sub.2 or 1.alpha.-hydroxyprevitamin D.sub.4, with less hypercalcemia than the same amount of activated vitamin D.sub.2 or D.sub.4 administered orally, the 1.alpha.-hydroxyprevitamin D being in a form which is substantially pure, crystalline, solvent-free, stable at room temperature and substantially free of its thermal isomer.
A method for treating psoriasis in a human being suffering therefrom, comprising administering orally to the human being a therapeutically effective amount of a solvent-free 1.alpha.-hydroxyprevitamin D, wherein said 1.alpha.-hydroxyprevitamin D is selected from the group consisting of 1.alpha.,25-dihydroxy-previtamin D.sub.3 ;
- 1.alpha.,24,25-trihydroxy-previtamin D.sub.3 ;
- 1.alpha.-hydroxy-previtamin D.sub.3 ;
- 1.alpha.,24-dihydroxy-previtamin D.sub.3 ;
- and 1.alpha.,24-dihydroxy-25-fluoro-previtamin D.sub.3, and wherein the 1.alpha.-hydroxyprevitamin D is substantially pure, crystalline, stable at room temperature and substantially free of its thermal isomer.
A method for treating psoriasis in a human being suffering therefrom, comprising administering orally to the human being a therapeutically effective amount of 1.alpha.,25-dihydroxyprevitamin D.sub.3 with less hypercalcemia than the same amount of activated vitamin D.sub.3 administered orally, the 1.alpha.,25-dihydroxyprevitamin D.sub.3 being substantially pure, crystalline, solvent-free, stable at room temperature and substantially free of its thermal isomer.
A composition in a unit dosage form comprising an oral 1.alpha.-hydroxyprevitamin D formulation suitable for use in a human and having improved bioavailability to reduce erythema, scaling and thickness associated with psoriasis, said formulation comprising:
- an amount of a 1.alpha.-hydroxyprevitamin D.sub.3 in a form which is substantially pure, crystalline and solvent-free, stable at room temperature and substantially free of its thermal isomer, and
- a pharmaceutically acceptable carrier.
A composition in a unit dosage form comprising an oral 1.alpha.-hydroxyprevitamin D formulation suitable for use in a human and having improved bioavailability to reduce erythema, scaling and thickness associated with psoriasis, said formulation comprising:
- an amount of 1.alpha.,24-dihydroxyprevitamin D.sub.2 in a form which is substantially pure, crystalline and solvent-free, stable at room temperature and substantially free of its thermal isomer, and
- a pharmaceutically acceptable carrier.
A composition in a unit dosage form comprising an oral 1.alpha.-hydroxyprevitamin D formulation, said formulation comprising:
- an amount of 1.alpha.-hydroxyprevitamin D.sub.2 in a form which is substantially pure, crystalline and solvent-free, stable at room temperature and substantially free of its thermal isomer, and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.